Purchase of 177Lu- Dotatate (Lutathera ®) to treat patients with neuroendocrine tumours
A Voluntary Ex-Ante Transparency (VEAT) Notice
by THE ROYAL MARSDEN NHS FOUNDATION TRUST
- Source
- Find a Tender
- Type
- Contract (Supply)
- Duration
- not specified
- Value
- £4M
- Sector
- HEALTH
- Published
- 22 Jan 2021
- Delivery
- not specified
- Deadline
- n/a
Related Terms
Location
London
Geochart for 2 buyers and 1 suppliers
2 buyers
- Royal Marsden NHS Trust London
1 supplier
Description
Purchase of 177Lu- Dotatate (Lutathera ®) to treat patients with neuroendocrine tumours
Total Quantity or Scope
The Royal Marsden Hospital NHS Foundation Trust needs to purchase 177Lu- Dotatate (Lutathera ®) to treat patients with neuroendocrine tumours
Award Detail
| 1 | Advanced Accelerator Application (London)
|
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
Legal Justification
177Lu- Dotatate is used to treat patients with neuroendocrine tumours; currently this is the only licensed product on the market to treat this tumour and AAA is the sole distributor in the UK.
Reference
- FTS 001348-2021